Looks like you’re on the UK site. Choose another location to see content specific to your location
GlaxoSmithKline joined by MMV on tropical diseases pool venture
GlaxoSmithKline has been joined by the Medicines for Malaria Venture (MMV) as a contributor to a major initiative to further research into tropical disease.
The not-for-profit venture has agreed to contribute a selection of patents to the Pool for Open Innovation against Neglected Tropical Diseases, which allows participating organisations to share expertise on conditions such as malaria.
GlaxoSmithKline was the first major pharmaceutical company to suggest a pool for neglected tropical disease in February 2009 and has since been joined by Alnylam Pharmaceuticals and the Massachusetts Institute of Technology in providing intellectual property contributions.
Don Joseph, chief operating officer for the pool's administrator BIO Ventures for Global Health, said the participation of a global product development partnership such as MMV will aid the effectiveness of the scheme.
He said it "opens a new dimension for the Pool for Open Innovation by demonstrating the range of organisations supporting the Pool through open access and application of their intellectual property".
Earlier this year, GlaxoSmithKline was named top of the Access to Medicine Foundation's second Access of Medicines Index, recognising its healthcare initiatives in developing nations.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard